Formulation And Evaluation Of Mouth-Dissolving Tablets Of Tramadol Hydrochlorhyde

Abstract

The primary objective of this investigation was to design, optimize, and critically evaluate patient-centric Mouth-Dissolving Tablets (MDTs) of Tramadol Hydrochloride (HCl) to circumvent dysphagia challenges, eliminate standard gastric lag times, and provide an ultra-rapid analgesic onset for managing acute breakthrough pain. The delivery matrices were fabricated utilizing the cost-effective and industrially efficient direct compression method. To counter the intense native bitterness of the drug and balance fast oral disintegration with high mechanical durability, innovative cross-linked functional polymer cores—specifically Doshion P544 and Super D33— were implemented as super-disintegrant elements in systematic concentration steps (5.0%, 7.5%, and 10.0% w/w) within a highly compressible core background of microcrystalline cellulose and spray-dried D-mannitol. The raw multi-particulate systems were screened for precompression flow kinetics, demonstrating exceptional flow properties suited for close-tolerance tableting. The compressed tablets met all official compendial limits for uniformity, thickness, and weight configuration. Systematic evaluation highlighted formulation TRMDLF3—containing 10 mg (10.0% w/w) of Doshion P544—as the optimized candidate across all criteria. TRMDLF3 demonstrated outstanding mechanical integrity, yielding an average hardness of 3.45 kg/cm² and a fractional friability loss of only 0.77%, well within industrial guidelines. Crucially, the optimized system demonstrated a rapid wetting time of 18 ± 2 seconds and an outstanding in vitro disintegration time of 22 ± 3 seconds in simulated salivary fluid (pH 6.8), leaving zero gritty residues. Volunteer taste panels confirmed complete masking of the bitter drug entity. Furthermore, in vitro dissolution tracking in simulated saliva revealed that TRMDLF3 achieved a premier release profile, unlocking 81.66% of the active analgesic within 5 minutes and reaching an exhaustive 98.21% cumulative dissolution within 15 minutes. This structural approach confirms that combining direct compression with optimized ratios of functional ionic resins like Doshion P544 provides an effective method for manufacturing superior mouth-dissolving tablets, offering significantly enhanced clinical compliance and rapid analgesic performance